Clinical Trial

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-03-06; most recent amendment 2026-06-25.
Trial Details
NCT Number NCT06869551
Lead Sponsor Bristol-Myers Squibb
Conditions Juvenile Psoriatic Arthritis
Enrollment 60 participants
Start Date 2025-03-13
Primary Completion 2030-03-06 (estimated)
Study Completion 2031-03-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-26